2018 American Transplant Congress
Safety and Efficacy of Rabbit Anti-Thymocyte Globulin Induction in Pediatric Patients Undergoing Cardiac Transplantation
Purpose: Limited data are available in pediatric cardiac transplant patients that focus on the safety and efficacy of rabbit anti-thymocyte globulin (rATG) induction therapy. The…2018 American Transplant Congress
Developing a Rationale for an Appropriate Immunosuppressive Regimen in Lung vs Kidney Transplant Recipients: Effects of Induction Therapy
IntroductionThe appropriate use of Thymoglobulin (ATG) or Basiliximab as induction therapy is not fully understood. We studied circulating cytokine profiles following kidney and lung transplantation…2018 American Transplant Congress
Decreased Long-Term Survival with Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients
Henry Ford Transplant Institute, Detroit, MI.
Purpose: Long-term consequences of immunosuppression on the elderly is still unclear. This data to evaluates long-term outcomes for younger (Y) versus elderly (E) kidney transplant…2018 American Transplant Congress
Less Induction Therapy Means Fewer Early Readmissions with No Change in Rejection or Infection
Vanderbilt University Medical Center, Nashville, TN.
PURPOSE:In heart transplant, induction may allow for delay of calcineurin inhibitor initiation and renal recovery. Literature comparing lymphocyte-depleting and non-depleting induction conflicts in rejection rate…2018 American Transplant Congress
Adjusted Body Weight Dosing of Rabbit Antithymocyte Globulin in Obese Renal Transplant Recipients Preserves Excellent Clinical Outcomes at 3 Years and Improves the Value of Care
University of Virginia Health System, Charlottesville, VA.
There is significant variability in antithymocyte globulin (ATG) dosing practices among centers. In the obese population, use of total body weight (TBW) vs. adjusted body…2018 American Transplant Congress
Thymoglobulin Induction in HIV Positive Kidney Transplant Recipients: Report on Transplant and HIV Outcomes
Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA.
Introduction: Kidney transplant outcomes in HIV positive recipients are similar to HIV negative recipients. However, high published rates of acute rejection are a challenge. There…2017 American Transplant Congress
Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…2017 American Transplant Congress
Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.
Weill Cornell Medical Center, New York, NY
Background: Although it is well established that kidney transplant (KT) in the elderly is beneficial and safe, there is limited literature on the appropriate choice…2017 American Transplant Congress
Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.
University of Maryland Medical Center, Baltimore, MD
BackgroundDirect-acting antiviral agents (DAAs) have improved treatment outcomes for Hepatitis C virus (HCV). Given high rates of treatment success with few side effects, eradication of…2017 American Transplant Congress
Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal.
Transplant Surgery, Brigham and Women's Hospital, Boston
Introduction: In a previous study by our group, rabbit antithymocyte globulin (r-ATG) induction was associated with lower rates of rejection when compared to basiliximab in…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 31
- Next Page »